Bevacizumab biosimilar - Bio-Thera Solutions

Drug Profile

Bevacizumab biosimilar - Bio-Thera Solutions

Alternative Names: BAT-1706

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bio-Thera Solutions
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I Cancer

Most Recent Events

  • 20 Oct 2017 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Recurrent, Metastatic disease) in China (IV) (NCT03329911)
  • 14 Jun 2016 Preclinical trials in Cancer in New Zealand (IV) before June 2016 (ACTRN12616000283471)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top